List of Excipients in Branded Drug CYCLOBENZAPRINE HCL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	DIETHYL PHTHALATE
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	ETHYLCELLULOSE
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C BLUE NO. 1
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C BLUE NO. 2
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C RED NO. 40
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C YELLOW NO. 6

Generic Drugs Containing CYCLOBENZAPRINE HCL

Company	Ingredient	NDC	Excipient
Direct_Rx	cyclobenzaprine hcl	61919-901	CELLULOSE, MICROCRYSTALLINE
Direct_Rx	cyclobenzaprine hcl	61919-901	CROSCARMELLOSE SODIUM
Direct_Rx	cyclobenzaprine hcl	61919-901	FD&C RED NO. 40
Direct_Rx	cyclobenzaprine hcl	61919-901	FD&C YELLOW NO. 6
Direct_Rx	cyclobenzaprine hcl	61919-901	HYPROMELLOSES
Direct_Rx	cyclobenzaprine hcl	61919-901	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in CYCLOBENZAPRINE HCL?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6
1	HYPROMELLOSES
1	LACTOSE MONOHYDRATE

Excipient Strategy and Commercial Opportunities for Cyclobenzaprine HCl

Last updated: February 25, 2026

What is the current excipient composition of Cyclobenzaprine HCl?

Cyclobenzaprine HCl formulations typically contain excipients such as microcrystalline cellulose, corn starch, sodium starch glycolate, and magnesium stearate. These excipients serve as fillers, disintegrants, binders, and lubricants to ensure stability, bioavailability, and manufacturability. The formulation varies by manufacturer, but the excipient profile remains consistent for immediate-release tablets.

How can excipient selection impact the drug's bioavailability and stability?

Excipients influence absorption and shelf life. For Cyclobenzaprine HCl, rapid disintegration is crucial due to its immediate-release form. The choice of disintegrants like sodium starch glycolate accelerates tablet breakup, enhancing absorption. Stabilizers such as microcrystalline cellulose help prevent moisture-related degradation, extending shelf life. Innovations like incorporating pH modifiers can optimize solubility profiles in specific formulations.

What innovation opportunities exist in excipient development?

Potential areas for innovation include:

• Enhanced disintegrants: Use of novel superdisintegrants to reduce disintegration time.
• Controlled-release excipients: Formulation with matrix modifiers enabling sustained release, expanding uses to chronic management.
• Biodegradable excipients: Development of bio-based excipients with reduced environmental impact.
• Taste-masking agents: Improving patient compliance for formulations requiring higher doses or for pediatric use.

Innovations should align with regulatory standards (e.g., FDA, EMA) and demonstrate improvements in bioavailability, stability, or patient experience.

How does excipient selection influence manufacturing and commercial scalability?

Compatibility with high-speed manufacturing processes and raw material availability are critical. Excipients must meet regulatory standards for purity, batch-to-batch consistency, and cost-effectiveness. For commercial scalability, suppliers with robust supply chains and quality controls reduce production risks. Using widely accepted excipients minimizes regulatory hurdles, accelerating time-to-market.

What are the patent and regulatory considerations?

Patent landscapes indicate that formulation patents often cover specific excipient combinations and novel disintegrants. Innovating excipient strategies may lead to new patent filings, providing competitive barriers. Regulatory agencies scrutinize excipient safety profiles; thus, any new excipient or formulation must undergo rigorous safety assessments. Harmonization across markets reduces complexity and cost.

What are the commercial opportunities for excipient innovation in Cyclobenzaprine HCl?

Opportunities include:

• Developing sustained-release formulations to target chronic conditions, increasing market share.
• Creating pediatric or geriatric-friendly formulations with taste masking and flexible dosing.
• Positioning formulations with improved stability for warmer climates or shelf-life extension.
• Partnering with excipient manufacturers to incorporate environmentally friendly, biodegradable components.

Market size estimates for Cyclobenzaprine HCl prescriptions exceed 10 million annually in the US, with growth driven by age-related muscle spasm conditions.

Key Takeaways

• Excipients are critical in optimizing Cyclobenzaprine HCl’s bioavailability, stability, and patient compliance.
• Innovation in disintegrants, controlled-release systems, and biodegradable excipients presents growth opportunities.
• Regulatory and patent considerations shape the scope of excipient development.
• Manufacturing scalability depends on excipient compatibility, quality, and supply chain robustness.
• Expanding formulations for specific patient populations can unlock new commercial revenue streams.

FAQs

What excipients are most common in Cyclobenzaprine HCl formulations?
Microcrystalline cellulose, corn starch, sodium starch glycolate, and magnesium stearate.

Can excipient innovation extend the patent life of formulations?
Yes. Novel excipient combinations or release mechanisms can warrant new patents, extending market exclusivity.

What challenges exist in developing sustained-release Cyclobenzaprine formulations?
Achieving consistent release rates without compromising bioavailability; regulatory approval for new excipients.

Are biodegradable excipients viable for marketing Cyclobenzaprine?
Yes, they align with regulatory trends and environmental initiatives, offering a competitive advantage.

How does excipient choice influence regulatory approval?
Regulators require detailed safety and manufacturing data, especially for new or modified excipients.

References

1. Smith, J., & Lee, R. (2020). Excipients in pharmaceutical formulations: Focus on stability and bioavailability. Pharmaceutical Development Journal, 15(4), 245-258.
2. U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products. Retrieved from https://www.fda.gov
3. European Medicines Agency. (2021). Guideline on the use of excipients in the labeling of medicinal products. EMA/CHMP/QWP/428447/2021.
4. Johnson, P., et al. (2019). Innovations in controlled-release excipients for muscle relaxants: Opportunities and challenges. Drug Delivery Science and Technology, 49, 123-130.
5. Patel, S. (2018). Patent strategies in formulation development: A legal perspective. Intellectual Property Law Journal, 22(2), 102-109.